Enzymatica completes acquisition of Zymetech and includes new board members and representative to the nomination committee
April 01 2016 - 8:34AM
Enzymatica AB (publ)
("Enzymatica") has today completed the acqusition of Zymetech and
taken ownership of 99.5 percent of the shares in Zymetech ehf.
("Zymetech") for a purchase price of approximately SEK 76 million
through an issue in kind of 20,905,942 new shares and 3,982,084 new
warrants in Enzymatica. Through the issue in kind, Enzymatica's
share capital increases to SEK 1,834,695 divided into 45,867,380
shares. In connection therewith, two new board members and one new
representative to the nomination committee will take up
office.
Enzymatica has today completed the acquisition and
became the owner of 99.5 percent of the shares in the
Icelandic company Zymetech, in accordance with previous press
releases. The purchase price for the Zymetech shares amounts
to approximately SEK 76 million, based on a share price of 3.45 SEK
per share, and has been paid through an issue in kind of 20,905,942
new shares and 3,982,084 new warrants in Enzymatica. The issue in
kind increases Enzymatica's share capital to SEK 1,834,695 divided
into 45,867,380 shares.
The acquisition and the issue in kind were
approved at an extra general meeting on 15 February 2016. As a
result of the completion of the acquisition, Guðmundur Pálmason
assume a position in the nomination committee of Enzymatica, and
Guðmundur Pálmason and Sigurgeir Guðlaugsson assume positions at
the board of directors of Enzymatica until the end of the next
annual general meeting, in accordance with the decision of the
extra general meeting on 15 February 2016.
Necessary registrations with the Swedish Companies
Registration Office and Euroclear Sweden AB will be finalized
during the upcoming weeks.
For
further information, contact:
Fredrik Lindberg, CEO Enzymatica AB
Phone: 0708-86 53 70 | E-mail:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bankaktiebolag.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#1999747
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024